Tags

Type your tag names separated by a space and hit enter

The role of olmesartan medoxomil in the management of hypertension.
Drugs. 2004; 64(24):2731-9.D

Abstract

Intensive blood pressure control is a desirable and obtainable goal in patients with hypertension, according to the most recent treatment guidelines from Europe and the US. Achieving target blood pressure depends on the efficacy of antihypertensive treatment and patient compliance. Olmesartan medoxomil, a non-peptidergic angiotensin AT1 receptor antagonist, has been shown to be effective and well tolerated. Continuation of initial treatment is higher with AT1 receptor antagonists than for any other class of antihypertensive drugs. Olmesartan medoxomil may also have end-organ protective effects that provide additional clinical benefit. Optimal blood pressure control may be achieved faster if initial treatment contains the most efficacious and well tolerated antihypertensive drug or drugs. The ongoing European study, known as OLMEBEST (Efficacy and safety of OLMEsartan: reduction of Blood pressure in the treatment of patients suffering from mild to moderate ESsenTial hypertension), will provide important information on the use of olmesartan medoxomil as an initial treatment for hypertension.

Authors+Show Affiliations

Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charité-University Medicine Berlin, Berlin, Germany. thomas.unger@charite.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

15563246

Citation

Unger, Thomas, et al. "The Role of Olmesartan Medoxomil in the Management of Hypertension." Drugs, vol. 64, no. 24, 2004, pp. 2731-9.
Unger T, McInnes GT, Neutel JM, et al. The role of olmesartan medoxomil in the management of hypertension. Drugs. 2004;64(24):2731-9.
Unger, T., McInnes, G. T., Neutel, J. M., & Böhm, M. (2004). The role of olmesartan medoxomil in the management of hypertension. Drugs, 64(24), 2731-9.
Unger T, et al. The Role of Olmesartan Medoxomil in the Management of Hypertension. Drugs. 2004;64(24):2731-9. PubMed PMID: 15563246.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of olmesartan medoxomil in the management of hypertension. AU - Unger,Thomas, AU - McInnes,Gordon T, AU - Neutel,Joel M, AU - Böhm,Michael, PY - 2004/11/26/pubmed PY - 2005/3/11/medline PY - 2004/11/26/entrez SP - 2731 EP - 9 JF - Drugs JO - Drugs VL - 64 IS - 24 N2 - Intensive blood pressure control is a desirable and obtainable goal in patients with hypertension, according to the most recent treatment guidelines from Europe and the US. Achieving target blood pressure depends on the efficacy of antihypertensive treatment and patient compliance. Olmesartan medoxomil, a non-peptidergic angiotensin AT1 receptor antagonist, has been shown to be effective and well tolerated. Continuation of initial treatment is higher with AT1 receptor antagonists than for any other class of antihypertensive drugs. Olmesartan medoxomil may also have end-organ protective effects that provide additional clinical benefit. Optimal blood pressure control may be achieved faster if initial treatment contains the most efficacious and well tolerated antihypertensive drug or drugs. The ongoing European study, known as OLMEBEST (Efficacy and safety of OLMEsartan: reduction of Blood pressure in the treatment of patients suffering from mild to moderate ESsenTial hypertension), will provide important information on the use of olmesartan medoxomil as an initial treatment for hypertension. SN - 0012-6667 UR - https://www.unboundmedicine.com/medline/citation/15563246/The_role_of_olmesartan_medoxomil_in_the_management_of_hypertension_ L2 - https://dx.doi.org/10.2165/00003495-200464240-00002 DB - PRIME DP - Unbound Medicine ER -